NCT03331341View on ClinicalTrials.gov

Doxorubicin Hydrochloride, Pembrolizumab, Vinblastine, and Dacarbazine in Treating Patients With Classical Hodgkin Lymphoma

PHASE1/PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 9, 2019

Primary Completion Date

December 21, 2023

Study Completion Date

December 21, 2023

Conditions

Classical Hodgkin Lymphoma

Interventions

DRUG

Dacarbazine

Given IV

DRUG

Doxorubicin Hydrochloride

Given IV

OTHER

Laboratory Biomarker Analysis

Correlative studies

BIOLOGICAL

Pembrolizumab

Given IV

DRUG

Vinblastine

Given IV

Trial Locations (1)

98109

Fred Hutch/University of Washington Cancer Consortium, Seattle

All Listed Sponsors

lead

University of Washington

OTHER

NCT03331341 - Doxorubicin Hydrochloride, Pembrolizumab, Vinblastine, and Dacarbazine in Treating Patients With Classical Hodgkin Lymphoma | Biotech Hunter | Biotech Hunter